Barahona Afonso AF, Joao CM. The production processes and biological effects of intravenous immunoglobulin. Biomolecules 2016;6:15.Barahona AfonsoAFJoaoCM.The production processes and biological effects of intravenous immunoglobulin. Biomolecules2016;6:15.10.3390/biom6010015Search in Google Scholar
Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma—aspects of yield and virus safety. Biotechnol J 2006;1:148–63.BuchacherAIbererG.Purification of intravenous immunoglobulin G from human plasma—aspects of yield and virus safety. Biotechnol J2006;1:148–63.10.1002/biot.200500037Search in Google Scholar
Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28:737–64.EiblMM.History of immunoglobulin replacement. Immunol Allergy Clin North Am2008;28:737–64.10.1016/j.iac.2008.06.004Search in Google Scholar
Greenbaum BH. Differences in immunoglobulin preparations for intravenous use: a comparison of six products. Am J Pediatr Hematol Oncol 1990;12:490–6.GreenbaumBH.Differences in immunoglobulin preparations for intravenous use: a comparison of six products. Am J Pediatr Hematol Oncol1990;12:490–6.10.1097/00043426-199024000-00015Search in Google Scholar
Branch DR. Unraveling the IVIG mystique. Transfusion 2013;53:242–4.BranchDR.Unraveling the IVIG mystique. Transfusion2013;53:242–4.10.1111/trf.12053Search in Google Scholar
Schroeder HW Jr, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection 2012;40: 601–11.SchroederHWJrDoughertyCJ.Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection2012;40: 601–11.10.1007/s15010-012-0323-9Search in Google Scholar
Imbach P, Barandun S, d’Apuzzo V, et al. High dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228–31.ImbachPBarandunSd’ApuzzoV, High dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet1981;1:1228–31.10.1016/S0140-6736(81)92400-4Search in Google Scholar
Imbach P, Morell A. Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Int Rev Immunol 1989;5:181–8.ImbachPMorellA.Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Int Rev Immunol1989;5:181–8.10.3109/088301889090619858691051Search in Google Scholar
Schwartz SA. Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol 1990;10: 81–9.SchwartzSA.Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol1990;10: 81–9.10.1007/BF009181892187017Search in Google Scholar
Chipps E, Skinner C. Intravenous immunoglobulin: implications for use in the neurological patient. J Neurosci Nurs 1994;26:8–17.ChippsESkinnerC.Intravenous immunoglobulin: implications for use in the neurological patient. J Neurosci Nurs1994;26:8–17.10.1097/01376517-199402000-000028195653Search in Google Scholar
Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017;139:S1–S46.PerezEEOrangeJSBonillaF, Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol2017;139:S1–S46.10.1016/j.jaci.2016.09.02328041678Search in Google Scholar
Pendergrast J, Binnington B, Tong TN, et al. Incidence and risk factors for IVIG-mediated hemolysis. Blood 2017;130:2398.PendergrastJBinningtonBTongTN, Incidence and risk factors for IVIG-mediated hemolysis. Blood2017;130:2398.Search in Google Scholar
Branch DR. Anti-A and anti-B: what are they and where do they come from? Transfusion 2015;55(Suppl 2):S74–9.BranchDR.Anti-A and anti-B: what are they and where do they come from?Transfusion2015;55(Suppl 2):S74–9.10.1111/trf.1308726174901Search in Google Scholar
Quinti I, Pulvirenti F, Milito C, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion 2015;55:1067–74.QuintiIPulvirentiFMilitoC, Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion2015;55:1067–74.10.1111/trf.1293925532440Search in Google Scholar
Michelis FV, Branch DR, Scovell I, et al. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Transfusion 2014;54: 681–90.MichelisFVBranchDRScovellI, Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Transfusion2014;54: 681–90.10.1111/trf.1232923829192Search in Google Scholar
Branch DR, Hellberg A, Bruggeman CA, et al. ABO zygosity, but not secretor or Fc status, is a significant risk factor for IVIG-associated hemolysis. Blood 2018;131:830–5.BranchDRHellbergABruggemanCA, ABO zygosity, but not secretor or Fc status, is a significant risk factor for IVIG-associated hemolysis. Blood2018;131:830–5.10.1182/blood-2017-07-79615129305554Search in Google Scholar
Hoefferer L, Glauser I, Gaida A, et al. Isoagglutinin reduction by dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. Transfusion 2015;55(Suppl 2):S117–21.HoeffererLGlauserIGaidaA, Isoagglutinin reduction by dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. Transfusion2015;55(Suppl 2):S117–21.10.1111/trf.1308826174889Search in Google Scholar
Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013; 105:54–64.FunkMBGrossNGrossS, Thromboembolic events associated with immunoglobulin treatment. Vox Sang2013; 105:54–64.10.1111/vox.1202523398249Search in Google Scholar
Puga Yung G, Seebach JD, Baerenzung N, Pendergrast J, Cserti-Gazdewich C, Branch DR. IgG subclasses determined from eluates of DAT positive patients after high-dose IVIg therapy do not predict hemolysis and are primarily of the IgG2 subclass. Transfusion (in press).Puga YungGSeebachJDBaerenzungNPendergrastJCserti-GazdewichCBranchDR.IgG subclasses determined from eluates of DAT positive patients after high-dose IVIg therapy do not predict hemolysis and are primarily of the IgG2 subclass. Transfusion(in press).Search in Google Scholar
Moscow JA, Casper AJ, Kodis C, Fricke WA. Positive direct antiglobulin test results after intravenous immune globulin administration. Transfusion 1987;27:248–9.MoscowJACasperAJKodisCFrickeWA.Positive direct antiglobulin test results after intravenous immune globulin administration. Transfusion1987;27:248–9.10.1046/j.1537-2995.1987.27387235631.x3495913Search in Google Scholar
Robertson VM, Dickson LG, Romond EH, Ash RC. Positive antiglobulin tests due to intravenous immunoglobulin in patients who received bone marrow transplant. Transfusion 1987;27:28–31.RobertsonVMDicksonLGRomondEHAshRC.Positive antiglobulin tests due to intravenous immunoglobulin in patients who received bone marrow transplant. Transfusion1987;27:28–31.10.1046/j.1537-2995.1987.27187121468.x3101247Search in Google Scholar
Whitsett CF, Pierce JA, Daffin LE. Positive direct antiglobulin tests associated with intravenous gamma globulin use in bone marrow transplant recipients. Transplantation 1986;41: 663–4.WhitsettCFPierceJADaffinLE.Positive direct antiglobulin tests associated with intravenous gamma globulin use in bone marrow transplant recipients. Transplantation1986;41: 663–4.10.1097/00007890-198605000-00026Search in Google Scholar
Thorpe SJ, Fox B, Heath A, Behr-Gross M-E, Virata ML, Yu M-Y. International collaborative study to assess candidate reference preparations to control the level of anti-D in IVIG for use in Europe and the United States. Biologicals 2006;34: 209–12.ThorpeSJFoxBHeathABehr-GrossM-EVirataMLYuM-Y.International collaborative study to assess candidate reference preparations to control the level of anti-D in IVIG for use in Europe and the United States. Biologicals2006;34: 209–12.10.1016/j.biologicals.2005.11.001Search in Google Scholar
Sakem B, Matozan K, Nydegger UE, Weigel G, Griesmacher A, Risch L. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations. Isr Med Assoc J 2013;15:617–21.SakemBMatozanKNydeggerUEWeigelGGriesmacherARischL.Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations. Isr Med Assoc J2013;15:617–21.Search in Google Scholar
Thorpe SJ, Fox BJ, Dolman CD, Lawrence J, Thorpe R. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sang 2003;85:80–4.ThorpeSJFoxBJDolmanCDLawrenceJThorpeR.Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sang2003;85:80–4.10.1046/j.1423-0410.2003.00336.xSearch in Google Scholar
Turner CE, Thorpe SJ, Brasher MD, Thorpe R. Anti-Rh D activity of commercial intravenous immunoglobulin preparations. Vox Sang 1999;76:55–8.TurnerCEThorpeSJBrasherMDThorpeR.Anti-Rh D activity of commercial intravenous immunoglobulin preparations. Vox Sang1999;76:55–8.10.1046/j.1423-0410.1999.7610055.xSearch in Google Scholar
Garratty G. Problems associated with passively transfused blood group alloantibodies. Am J Clin Pathol 1998;109: 769–77.GarrattyG.Problems associated with passively transfused blood group alloantibodies. Am J Clin Pathol1998;109: 769–77.10.1093/ajcp/109.6.769Search in Google Scholar
Lucas GS, Jobbins K, Bloom AL. Intravenous immunoglobulin and blood-group antibodies. Lancet 1987;2:742.LucasGSJobbinsKBloomAL.Intravenous immunoglobulin and blood-group antibodies. Lancet1987;2:742.10.1016/S0140-6736(87)91100-7Search in Google Scholar
Romer J, Morgenthaler J-J, Scherz R, Skvaril F. Characterization of various immunoglobulin preparations for intravenous application I: protein composition and antibody content. Vox Sang 1982;42:62–73.RomerJMorgenthalerJ-JScherzRSkvarilF.Characterization of various immunoglobulin preparations for intravenous application I: protein composition and antibody content. Vox Sang1982;42:62–73.10.1159/0004608506977944Search in Google Scholar
Kluge A, Dopfer R, Pfeiffer-Wolf I, Roelcke D. Immunoglobulin high-dose therapy: RBC-alloantibodies in commercial preparations and haemolytic anaemia: a case report. Beitr Infusionsther Transfusionsmed 1994;32:474–5.KlugeADopferRPfeiffer-WolfIRoelckeD.Immunoglobulin high-dose therapy: RBC-alloantibodies in commercial preparations and haemolytic anaemia: a case report. Beitr Infusionsther Transfusionsmed1994;32:474–5.Search in Google Scholar
Lichtiger B, Rogge K. Spurious serologic test restuls in patients receiving infusions of intravenous immune gammaglobulin. Arch Pathol Lab Med 1991;115:467–9.LichtigerBRoggeK.Spurious serologic test restuls in patients receiving infusions of intravenous immune gammaglobulin. Arch Pathol Lab Med1991;115:467–9.Search in Google Scholar
Garcia L, Huh YO, Fischer HE, Lichtiger B. Postivie immunohematologic and serologic test results due to high dose intravenous immune globulin administration. Transfusion 1987;27:503.GarciaLHuhYOFischerHELichtigerB.Postivie immunohematologic and serologic test results due to high dose intravenous immune globulin administration. Transfusion1987;27:503.10.1046/j.1537-2995.1987.27688071707.x3318029Search in Google Scholar
Steiner EA, Butch SH, Carey JL, Oberman HA. Passive anti-D from intravenous immune serum globulin. Transfusion 1983;23:363.SteinerEAButchSHCareyJLObermanHA.Passive anti-D from intravenous immune serum globulin. Transfusion1983;23:363.10.1046/j.1537-2995.1983.23483276885.x6410556Search in Google Scholar
Hoppe I. Antibody screening of commercially available immunoglobulins. erythrocyte-, HLA- and autoantibodies. Blut 1979;39:9–16.HoppeI.Antibody screening of commercially available immunoglobulins. erythrocyte-, HLA- and autoantibodies. Blut1979;39:9–16.10.1007/BF01008070465744Search in Google Scholar
Lang GE, Veldhuis B. Immune serum globulin—a cause for anti-Rh(D) passive sensitization. Am J Clin Pathol 1973;60:205–7.LangGEVeldhuisB.Immune serum globulin—a cause for anti-Rh(D) passive sensitization. Am J Clin Pathol1973;60:205–7.10.1093/ajcp/60.2.2054198286Search in Google Scholar
